Hepatocellular adenoma epidemiology and demographics

Jump to: navigation, search

Hepatocellular adenoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hepatocellular adenoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hepatocellular adenoma epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hepatocellular adenoma epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hepatocellular adenoma epidemiology and demographics

CDC on Hepatocellular adenoma epidemiology and demographics

Hepatocellular adenoma epidemiology and demographics in the news

Blogs on Hepatocellular adenoma epidemiology and demographics

Directions to Hospitals Treating Hepatocellular adenoma

Risk calculators and risk factors for Hepatocellular adenoma epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Zahir Ali Shaikh, MD[2]

Overview

Hepatocellular adenoma is more common in women in Western countries where they are exposed to higher doses of oral contraceptives. The estimated incidence is 3 per 100,000 individuals/year and is 3 to 4 per 100,000 individuals with long term history of oral contraceptive use. It is more common in women of childbearing age who take oral contraceptives and can rarely occur in men who take long term anabolic androgenic steroids.

Epidemiology and Demographics

Incidence

Prevalence

  • Prevalence of hepatocellular adenoma is difficult to asses because of the large proportion of adenomas not presenting with conventional symptoms.
  • The prevalence of hepatocellular adenoma was increased in the 1970s following the introduction of oral contraception in Western countries.[4]

Age

Gender

References

  1. Barthelmes L, Tait IS (2005). "Liver cell adenoma and liver cell adenomatosis". HPB (Oxford). 7 (3): 186–96. doi:10.1080/13651820510028954. PMC 2023950. PMID 18333188.
  2. Nault, Jean-Charles; Couchy, Gabrielle; Balabaud, Charles; Morcrette, Guillaume; Caruso, Stefano; Blanc, Jean-Frederic; Bacq, Yannick; Calderaro, Julien; Paradis, Valérie; Ramos, Jeanne; Scoazec, Jean-Yves; Gnemmi, Viviane; Sturm, Nathalie; Guettier, Catherine; Fabre, Monique; Savier, Eric; Chiche, Laurence; Labrune, Philippe; Selves, Janick; Wendum, Dominique; Pilati, Camilla; Laurent, Alexis; De Muret, Anne; Le Bail, Brigitte; Rebouissou, Sandra; Imbeaud, Sandrine; Bioulac-Sage, Paulette; Letouzé, Eric; Zucman-Rossi, Jessica; Laurent, Christophe; Saric, Jean; Frulio, Nora; Castain, Claire; Dujardin, Fanny; Benchellal, Zin; Bourlier, Pascal; Azoulay, Daniel; Luciani, Alain; Pageaux, Georges-Philippe; Fabre, Jean-Michel; Vilgrain, Valerie; Belghiti, Jacques; Bancel, Brigitte; Boleslawski, Emmanuel; Letoublon, Christophe; Vaillant, Jean Christophe; Prévôt, Sophie; Castaing, Denis; Jacquemin, Emmanuel; Peron, Jean Marie; Quaglia, Alberto; Paye, François; Terraciano, Luigi; Mazzaferro, Vincenzo; Saint Paul, Marie Christine; Terris, Benoit (2017). "Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation". Gastroenterology. 152 (4): 880–894.e6. doi:10.1053/j.gastro.2016.11.042. ISSN 0016-5085.
  3. J. B. Rooks, H. W. Ory, K. G. Ishak, L. T. Strauss, J. R. Greenspan, A. P. Hill & C. W. Jr Tyler (1979). "Epidemiology of hepatocellular adenoma. The role of oral contraceptive use". JAMA. 242 (7): 644–648. PMID 221698. Unknown parameter |month= ignored (help)
  4. Védie, Anne-Laure; Sutter, Olivier; Ziol, Marianne; Nault, Jean-Charles (2018). "Molecular classification of hepatocellular adenomas: impact on clinical practice". Hepatic Oncology. 5 (1): HEP04. doi:10.2217/hep-2017-0023. ISSN 2045-0923.
  5. L. A. Heinemann, A. Weimann, G. Gerken, C. Thiel, M. Schlaud & T. DoMinh (1998). "Modern oral contraceptive use and benign liver tumors: the German Benign Liver Tumor Case-Control Study". The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception. 3 (4): 194–200. PMID 10036602. Unknown parameter |month= ignored (help)
  6. 6.0 6.1 Nault, Jean-Charles; Paradis, Valérie; Cherqui, Daniel; Vilgrain, Valérie; Zucman-Rossi, Jessica (2017). "Molecular classification of hepatocellular adenoma in clinical practice". Journal of Hepatology. 67 (5): 1074–1083. doi:10.1016/j.jhep.2017.07.009. ISSN 0168-8278.
  7. G. B. Coombes, J. Reiser, F. J. Paradinas & I. Burn (1978). "An androgen-associated hepatic adenoma in a trans-sexual". The British journal of surgery. 65 (12): 869–870. PMID 737424. Unknown parameter |month= ignored (help)

Linked-in.jpg